One Team. Many Voices.
Exceptional People and Culture
The lifeblood of our company is our exceptional people and culture. We have purposefully built the team with a focus on passionate scientists and company-builders who have hands-on experience translating groundbreaking science into important new medicines.
- Cynthia (Cindy) Collins
- Interim Chief Executive Officer
Cindy is interim Chief Executive Officer of Editas Medicine. She joined Editas Medicine’s Board of Directors in December 2018 and was named interim CEO in February 2019. Cindy is a recognized leader in cell and gene therapy, molecular diagnostics, life sciences, and therapeutics. Most recently, Cindy served as CEO of Human Longevity Inc. Prior, she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics, Inc. Cindy also served as President and CEO of…
- Charles Albright, Ph.D.
- Chief Scientific Officer
Charlie is Chief Scientific Officer of Editas Medicine. He joined Editas Medicine in August 2016 and is responsible for leading the team that is translating the promise of genome editing into a broad class of transformative genomic medicines. Charlie brings more than 25 years of life sciences industry and academic leadership experience to this role. Throughout his career, Charlie has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain,…
- Eric Ek
- Interim Chief Financial Officer
Eric Ek is interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Editas Medicine. He joined Editas Medicine in March 2019 and is responsible for leading the finance, investor relations, information technology, and facilities teams. Eric has more than 30 years of strategic, financial, transactional and operational experience at a variety of companies. Since July 2017, Eric has been a managing director at FTI as a member of the Office of the CFO practice within the corporate…
- Timothy (Tim) D. Hunt
- Senior Vice President, Corporate Affairs
Tim is Senior Vice President, Corporate Affairs at Editas Medicine. He joined Editas Medicine in January 2016 and oversees government affairs, global policy, human resources, corporate communications, and market development. Prior to joining Editas Medicine, Tim served as Senior Vice President of Public Affairs for Cubist Pharmaceuticals, until the company was acquired by Merck in 2015. Before joining Cubist, Tim spent several years at Biogen Idec, where he most recently served as Vice President of Public Affairs, overseeing global communications….
- Vic Myer, Ph.D.
- Chief Technology Officer
Vic Myer is Editas Medicine’s Chief Technology Officer. He joined Editas Medicine in April 2015 and leads the team responsible for translating CRISPR technologies into medicines for treating serious, genetically-driven diseases. Prior to joining Editas Medicine, Vic served as Executive Director and Cambridge Site Head for the Developmental and Molecular Pathways Department at the Novartis Institutes for Biomedical Research Incorporated. During his tenure there, he also led the high-throughput biology team and oversaw the target discovery technologies platform. Vic was…
- Charlene Stern, J.D., Ph.D.
- Vice President and Head of Legal
Charlene was part of the team that launched Editas Medicine in 2013. As Head of Legal, she oversees and manages all legal matters, including corporate governance, securities compliance and SEC reporting, partnering and licensing transactions, financings, and intellectual property strategy. She also serves as Editas Medicine’s Corporate Secretary. Prior to Editas Medicine, Charlene was senior patent counsel at AVEO Oncology, where she was responsible for developing and executing AVEO’s intellectual property strategy. Earlier in her career, she was a senior…
- James Mullen
James C. Mullen joined the Editas Medicine Board of Directors as Chairman of the Board in March of 2018. Jim is a biotech leader with more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, Mr. Mullen served as Chief Executive Officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Before joining Patheon, Mr. Mullen served as Chief Executive Officer and President at Biogen, one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, Mr. Mullen held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Before joining Biogen, he held several manufacturing and engineering positions at SmithKline Beecham.
Mr. Mullen also serves on the Board of Directors of Insulet Corporation and Vicarius Pharma AG. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization.
Mr. Mullen holds a Bachelor of Science in Chemical Engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University.
- Cynthia (Cindy) Collins
- Interim Chief Executive Officer, Editas Medicine
Cindy is interim Chief Executive Officer of Editas Medicine. She joined Editas Medicine’s Board of Directors in December 2018 and was named interim CEO in February 2019.
Cindy is a recognized leader in cell and gene therapy, molecular diagnostics, life sciences, and therapeutics. Most recently, Cindy served as CEO of Human Longevity Inc. Prior, she served as the CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics, Inc. Cindy also served as President and CEO of GenVec, a publicly-traded vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses. Prior to Beckman Coulter, she served as President and CEO of Sequoia Pharmaceuticals, Inc., a venture-capital funded company developing antiviral drugs for HIV and HCV.
Earlier in her career, Cindy served as President of Clinical Micro Sensors, Inc., a wholly-owned subsidiary of Motorola, a molecular diagnostic company. Prior to Motorola, she spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President and General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. She began her career with Abbott Laboratories where she spent six years in various operating roles.
Cindy received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA from The University of Chicago Booth School of Business. She is a member of the board of directors for the ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, DermTech, Cavidi, and Biocare Medical.
- Andrew Hirsch
- Chief Financial Officer and Head of Corporate Development, Agios
Andrew Hirsch joined the Editas Medicine Board of Directors in May 2017 with more than 20 years of experience in a range of strategic and operating business roles, including more than 15 years in the biotech industry. Since September 2016, he has served as Chief Financial Officer at Agios, a biopharmaceutical company in the fields of cancer metabolism and rare genetic diseases. Prior to joining Agios, Mr. Hirsch served as President and Chief Executive Officer of BIND Therapeutics. Prior to joining BIND, Mr. Hirsch was Chief Financial Officer at Avila Therapeutics until its acquisition by Celgene. Prior to that, he held roles of increasing responsibility during his nearly 10-year tenure at Biogen, Inc., including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team.
Mr. Hirsch holds an MBA from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania.
- Jessica Hopfield
Jessica Hopfield is a scientist and business leader with more than two decades of experience in the medical and healthcare fields. She joined the Editas Medicine Board of Directors in February 2018. Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as an Independent Director on the Board of Directors of Insulet Corporation and of Radius Health. In addition, she is a strategic advisor and investor in start-up healthcare firms, including serving as a strategic advisor to the former independent director of rEVO Biologics.
Dr. Hopfield is a former Partner of McKinsey & Company in its global pharmaceuticals and medical devices practice, where she led work in strategy, R&D management, and marketing across pharmaceutical, biotech, medical device and consumer industries. Dr. Hopfield also held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing.
Dr. Hopfield earned a Bachelor of Science from Yale College, a Master of Business Administration from Harvard Graduate School of Business Administration as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University.
- David Scadden, M.D.
Dr. David Scadden joined the Editas Medicine Board of Directors in February 2019. David is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He founded and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and co-directs the Harvard Stem Cell Institute and is chairman emeritus and professor of the Harvard University Department of Stem Cell and Regenerative Biology. David has published more than 300 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem cell function.
David is the recipient of numerous honors including membership in the National Academy of Medicine, the American Academy of Arts and Sciences, is a Fellow of the American College of Physicians and the American Association for the Advancement of Science and awards from the American Society of Hematology, the Doris Duke Charitable Trust, the Ellison Medical Foundation, the Burroughs Wellcome Fund, and the Leukemia and Lymphoma Society. He has served on the board of scientific counselors for the National Cancer Institute; the board of external experts for the National Heart, Lung and Blood Institute; board of directors of the International Society for Stem Cell Research (ISSCR); and is an affiliate member of the Broad Institute of Harvard and MIT. He also serves on multiple editorial, scientific advisory boards, and corporate boards, including Agios Pharmaceuticals, Inc., and he is a scientific founder of Fate Therapeutics and Magenta Therapeutics.
David earned a BA from Bucknell University in English and an MD from Case Western Reserve School of Medicine. He also completed pre-medical studies at Columbia University. Dr. Scadden also holds honorary degrees including an AM from Harvard Medical School, a Sc.D. from Bucknell University, and an MD from Lund University in Sweden.
- Akshay Vaishnaw, M.D., Ph.D.
- President of Research and Development, Alnylam Pharmaceuticals
Dr. Vaishnaw joined the Editas Medicine Board of Directors in July 2016. He has served as Alnylam’s President of Research and Development since December 2017. Dr. Vaishnaw joined Alnylam in January 2006 as VP Clinical Research and since that time has held positions of increasing responsibility including SVP Clinical Research, EVP Research and Development, and Chief Medical Officer, before assuming his current role. From December 1998 through 2005, he held various positions in Medical Research at Biogen, Inc.
Dr. Vaishnaw received his M.D. from the University of Wales College of Medicine, U.K., and his Ph.D. from the University of London, U.K., in molecular immunology. He is also a Fellow of the Royal College of Physicians, U.K. He served on the board of directors of Visterra Inc., and the scientific advisory board of Scholar Rock Inc.
- Feng Zhang, Ph.D.
- Core Member, Broad Institute of MIT and Harvard; Investigator, McGovern Institute for Brain Research, Massachusetts Institute for Technology; W.M. Keck Career Development Professor, Departments of Brain and Cognitive Sciences and Biological Engineering, Massachusetts Institute of Technology; Robertson Investigator, New York Stem Cell Foundation
Feng Zhang joined the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard as a core member in 2011. Dr. Zhang is also an investigator at the McGovern Institute for Brain Research at MIT and an assistant professor at MIT with a joint appointment in the departments of brain and cognitive sciences and biological engineering. As a student, he played a major role in the development of optogenetics, a technology that allows the brain’s electrical activity to be controlled with light-sensitive proteins. He is now working to extend this molecular engineering approach to other aspects of brain function, such as gene expression, and to develop new approaches to understanding and eventually treating brain diseases. Dr. Zhang is a Searle Scholar and has received both a Director’s Transformative Research Award and a Directors? Pioneer Award from the National Institutes of Health. In 2012, he shared the UNC/Perl Prize for his role in the development of optogenetics.
Dr. Zhang holds an A.B. in chemistry and physics from Harvard College and a Ph.D. in chemistry from Stanford University.
- George Church, Ph.D.
- Professor of Genetics, Health Sciences and Technology, Harvard University and MIT; Director of the HMS NHGRI-Center of Excellence in Genomic Science; Director of the Personal Genome Project, Broad Institute and Wyss Harvard Institute of Biologically Inspired Engineering
George Church is a leading expert in human genetics and biotechnology. He has served as professor of genetics at Harvard Medical School since 1986 and currently serves as professor of health sciences and technology at Harvard and the Massachusetts Institute of Technology (MIT). He is also director of the U.S. Department of Energy Center on Bioenergy at Harvard and MIT and director of the National Institutes of Health Center of Excellence in Genomic Science at Harvard. Dr. Church helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. Dr. Church pioneered genome engineering, systems and synthetic biology, and concepts of molecular multiplexing and tags, and he has a successful track record of developing and transferring new technologies to more than 20 companies. Dr. Church has received numerous awards, including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the 2009 Promega Biotechnology Research Award from the American Society for Microbiology, and was honored in The Scientist’s Top 10 Innovations list in 2008.
Dr. Church holds a Ph.D. in biochemistry and molecular biology from Harvard University and a B.A. in zoology and chemistry from Duke University.
- J. Keith Joung, M.D., Ph.D.
- Associate Chief of Pathology for Research and Pathologist, Massachusetts General Hospital; Professor of Pathology, Harvard Medical School
J. Keith Joung currently serves as professor of pathology at Harvard Medical School and is associate chief of pathology for research and the Jim and Ann Orr Research Scholar at Massachusetts General Hospital (MGH). He is also a member of the Center for Cancer Research and Center for Computational and Integrative Biology at MGH.
Dr. Joung has been a pioneer in the development of important technologies for targeted genome editing and epigenome editing of human cells. He has received numerous awards including an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals.
Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. from Harvard Medical School and an A.B. in biochemical sciences from Harvard College.
- David R. Liu, Ph.D.
- Investigator, Howard Hughes Medical Institute; Professor of Chemistry and Chemical Biology, Harvard University; Vice-Chair of the Faculty and Core Faculty Member, Broad Institute of MIT and Harvard
David R. Liu is an accomplished chemist, biologist, and innovator. He currently serves as professor of chemistry and chemical biology at Harvard University, investigator of the Howard Hughes Medical Institute investigator, and vice-chair of the faculty and core institute member of the Broad Institute of Harvard and MIT. His research has advanced the fields of therapeutics discovery, laboratory evolution, macromolecular delivery, and genome editing. Dr. Liu’s insight and breadth led him to be tapped to serve as a JASON, an elite group of scientists who advise the U.S. government on matters of science and technology. Dr. Liu is also the recipient of numerous scientific distinctions, including the American Chemical Society Pure Chemistry and Arthur C. Cope Young Scholar Awards, the GlaxoSmithKline Chemistry Scholar Award, the AstraZeneca Pharmaceuticals Excellence in Chemistry Award, the Searle Scholars Award, the National Science Foundation (NSF) Faculty Early Career Development (CAREER) Award, the Sloan Foundation Fellowship, the Beckman Foundation Young Investigator Award, the Office of Naval Research Young Investigator Award and the university-wide Roslyn Abramson Award for undergraduate teaching at Harvard. Dr. Liu was named to the Popular Science “Brilliant 10” for young scientists in the U.S., as well as to the MIT TR100 for young innovators. In 2016 he was named one of the Top 20 Translational Researchers by Nature Biotechnology. His accomplishments also include groundbreaking research leading to the foundation of Ensemble Therapeutics and Permeon Biologics.
Dr. Liu holds a B.A. in chemistry from Harvard College and a Ph.D. in organic chemistry from the University of California, Berkeley.